Table 1:
Comparison of clinical and pathological data between two groups
| Characteristics | STT（n = 65） | UTT (n = 72) | P-value |
|---|---|---|---|
| Age (years), median (range) | 49 (18–67) | 52 (18–71) | 0.581 |
| Sex, n (%) | 0.667 | ||
| Male | 31 (47.7) | 37 (51.4) | |
| Female | 34 (52.3) | 35 (48.6) | |
| BMI (kg/m2), median (range) | 22.3 (16.1–29.8) | 22.7 (15.9–30.0) | 0.473 |
| Smokers, n (%) | 13 (22.3) | 16 (21.6) | 0.851 |
| Comorbidity, n (%) | 0.958 | ||
| Extrathoracic malignancy | 1 (1.5) | 2 (2.8) | |
| Chronic obstructive pulmonary disease | 9 (13.8) | 11 (15.2) | |
| Hypertension | 7 (10.8) | 8 (11.1) | |
| Diabetes mellitus | 3 (4.6) | 5 (6.9) | |
| Cardiac diseases | 4 (6.2) | 4 (5.6) | |
| Others | 1 (1.5) | 2 (2.8) | |
| None | 40 (61.6) | 40 (55.6) | |
| ASA classification, median (range) | 1 (1–3) | 1 (1–3) | >0.999 |
| QMG score | 3.1 ± 2.11 | 3.4 ± 1.97 | 0.206 |
| MGFA clinical classification, n (%) | 0.799 | ||
| I | 29 (44.7) | 35 (48.7) | |
| II | 31 (47.7) | 29 (40.2) | |
| III | 4 (6.2) | 6 (8.3) | |
| IV | 1 (1.4) | 2 (2.8) | |
| Maximal tumour size (cm) | 3.27 ± 1.49 | 3.41 ± 1.38 | 0.592 |
| Pathology, n (%) | 0.946 | ||
| Thymoma | 19 (29.2) | 22 (30.6) | |
| Thymic hyperplasia | 27 (41.6) | 32 (44.4) | |
| Thymic cyst | 18 (27.7) | 16 (22.2) | |
| Thymus atrophy | 1 (1.5) | 2 (2.8) | |
| WHO histologic type of thymomas, n (%) | 0.960 | ||
| A/AB | 8 (12.3) | 10 (13.9) | |
| B1/B2/B3 | 10 (15.4) | 12 (16.7) | |
| C | 1 (1.5) | 0 (0.0) | |
| Masaoka–Koga stage, n (%) | 0.291 | ||
| I | 15 (23.0) | 18 (25.0) | |
| II | 4 (6.2) | 4 (5.6) |
ASA: American Society of Anesthesiologists; BMI: body mass index; MGFA: Myasthenia Gravis Foundation of America; QMG: Quantitative Myasthenia Gravis; WHO: World Health Organization.